Azmi Nabulsi - 01 Sep 2022 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role
Chief Operating Officer
Signature
/s/ Larry Miller, Attorney-in-Fact for Azmi Nabulsi
Issuer symbol
PHAT
Transactions as of
01 Sep 2022
Net transactions value
$0
Form type
4
Filing time
02 Sep 2022, 16:05:34 UTC
Previous filing
20 May 2022
Next filing
20 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHAT Common Stock Award $0 +7,500 +22% $0.000000 41,971 01 Sep 2022 Direct F1, F2
holding PHAT Common Stock 2,355 01 Sep 2022 by 401(k) F3
holding PHAT Common Stock 785,700 01 Sep 2022 by Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") granted on September 1, 2022. Fifty percent (50%) of the total number of RSUs granted vest on each of March 1, 2023 and June 1, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2 Includes 1,093 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2022.
F3 Includes 1,511.80 shares acquired under the Phathom Pharmaceuticals, Inc. 401(k) plan.